文章核心观点 - Compass Therapeutics, Inc. (CMPX)被评级为Zacks Rank 2 (Buy),这表明公司的盈利前景有所改善[1][4][6] - 公司的盈利预测上调是导致评级上调的主要原因[2][7][9][10] - 盈利预测的变化是影响股价的最强大力量,因为机构投资者会根据盈利预测来计算公司的合理价值[5] 公司概况 - Compass Therapeutics, Inc.是一家生物制药公司[1] - 公司预计2024财年每股收益为-0.39美元,同比下降18.2%[9] - 过去3个月内,公司的盈利预测已上调20.1%[10] 投资评级 - Zacks评级系统将公司评为Rank 2 (Buy),位于Zacks覆盖股票的前20%,表明公司的盈利预测修正优于同行[11][13] - Zacks Rank 1和2的股票过去平均年收益率为25%,表现优于大盘[8]

alengo/E+ via Getty Images Topline Summary Compass Therapeutics (NASDAQ:CMPX) is an oncology-focused developmental biotech working on novel immunotherapies to treat different forms of solid tumor, with the most notable shots on goal being in the gastrointestinal cancers space. They have experienced significant declines in valuation through 2023 and 2024, despite being deep in late-stage clinical study. So today I want to take a look at their projects, what they've shared to date, and the outlook for potenti ...

Investor Contact ir@compasstherapeutics.com Media Contact "Vered has been a valued member of our executive team," added Carl L. Gordon, Chairman of the Board. "We thank Vered for her significant contributions to Compass and wish her the very best in her future endeavors." About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass's scientific focus is on the ...

_____________________________ For the transition period from _________________ to _________________ Registrant's telephone number, including area code: (617) 500-8099 _____________________________ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ ...

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update Enrollment is progressing well in COMPANION-002, a Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC). Enrollment is expected to be completed by mid-year 2024 with top-line data expected in the first quarter of 2025. Advanced CTX-8371 (PD-1 x PD-L1 bispecific antibody) into a first-in-human clinical study and dosed the first patient in Ap ...

CTX-009 抗体 - Compass Therapeutics, Inc. 宣布其 bispecific DLL4/VEGF-A 抗体 CTX-009 获得 FDA 快速通道认定[1] - CTX-009 与紫杉醇联合治疗在晚期胆道癌患者中显示出有希望的临床反应[2] - CTX-009 是一种同时阻断 Delta-like ligand 4 (DLL4) 和 vascular endothelial growth factor A (VEGF-A) 信号通路的双特异性抗体[3] 胆道癌患者情况 - 美国每年约有 23,000 例胆道癌患者，其中只有 10% 的患者处于早期阶段，大多数患者处于局部晚期或转移性胆道癌阶段[4] FDA 快速通道认定 - FDA 快速通道认定旨在帮助药物更快地到达患者，加快具有填补医疗需求潜力的药物的开发和审查[5] Compass Therapeutics 公司 - Compass Therapeutics 是一家致力于肿瘤治疗的临床阶段生物制药公司，专注于血管生成、免疫系统和肿瘤生长之间的关系[6]

BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced poster presentations on CTX-009, the Company's bispecific DLL4/VEGF-A antibody, at the Cholangiocarcinoma Foundation (CCF) 2024 Annual Conference to be held at the Salt Palace Convention Center in Salt Lake City, Utah from April 17–19, 2024. Presentation Details: P ...

Major Histocompatibility Complex Class I (MHC-I) negative tumors are refractory to immune-oncology therapies, including resistance to checkpoint blockers, due to the loss of the fundamental recognition of the tumor by CD8+ T-Cells, which drive the adaptive immune attack on the tumor. Immune responses were generated toward the MHC-I negative tumors by combining CTX-009 with CTX-471. This combination was surprisingly synergistic. The proposed mechanism for this effect suggests the involvement of NK-cells, whi ...

Today we will be looking at three penny stocks with the power to 10x your $1K investment. The three firms discussed below have outsized potential to turn a small capital allocation into a much larger return.Two of the three firms discussed below have very strong catalysts on their side. The other operates in the biotech sector which is notoriously volatile. Regardless, all three have a lot of untapped potential. Penny stocks are no different than any others from the perspective that good businesses create g ...

公司财务状况 - 公司自成立以来累计亏损3.15亿美元[125] - 预计未来几年内将继续承担重大支出和运营亏损[126] - 预计未来几年内也可能无法盈利[127] - 预计将需要大量资金来实现业务目标[129] - 预计现有资金将支持运营费用和资本支出至2026年中期[130] 临床试验风险 - 公司的业务发展依赖于临床试验并最终商业化[134] - 临床开发是漫长且昂贵的过程，结果不确定[137] - 临床试验可能会因多种因素而被暂停或终止[140] - 临床试验结果可能不足以获得监管批准[144] - 临床试验的中期和初步结果可能会随着更多患者数据的出现而发生变化[145] 市场监管批准风险 - FDA等监管机构对产品候选人的审批过程长期且不可预测[159] - 产品候选人可能无法获得批准的原因多种多样[160] - 申请市场监管批准需要提供足够证据[162] - FDA对新产品的审批能力可能受多种因素影响[166] - 任何产品候选者的市场监管批准可能受限制和条件[171] 市场推广风险 - 公司产品获得市场认可可能面临挑战[175] - 未来发生的不良事件可能导致更严格的监管和潜在的审批延迟[176] - 产品候选人的市场机会可能受限[179] - 建立营销、销售和分销能力存在风险[183] - 产品责任诉讼可能限制产品商业化[186] 知识产权风险 - 公司无法获得和维持产品候选人的专利保护可能影响竞争力[198] - 知识产权保护依赖于遵守各种程序、文件提交、费用支付等要求[202] - 知识产权诉讼可能对公司产生重大不利影响[205] - 公司依赖专利保护和保密协议来保护无法专利化的专有技术[206] - 公司可能会成为专利和其他知识产权诉讼的一方[208] 公司经营风险 - 公司可能依赖第三方合作伙伴进行产品候选者的发现、开发和商业化[221] - 公司竞争对手可能比我们更快地获得监管批准[225] - 我们需要扩大组织规模，但可能会遇到困难[226] - 我们高度依赖关键人员[227] - 如果我们未能保持适当和有效的财务报告内部控制，可能会影响我们准确和及时地制作财务报表的能力[228] 法律合规风险 - 公司受到反腐败、反洗钱、出口管制、制裁等法律监管[236] - 公司与政府机构的交易受到监管[237] - 公司未能遵守环境、健康和安全法律法规可能面临罚款或处罚[238] - 公司将继续因为成为上市公司而产生增加的成本[240] - 公司是一家新兴成长型公司和较小的报告公司，无法确定减少报告要求是否会影响投资者[241]